Biocon Biologics Limited (BBL) got off to a promising start to FY24 with an over two-fold increase in first-quarter revenues, truly reflecting the “Power of One” derived from the Company's transformative acquisition of the global biosimilars of its long-term partner Viatris. Driven by market share gains for its commercialized biosimilars in key markets and the … Continue reading Delivering on ‘Power of One’; Biocon Biologics starts FY24 on a Strong Footing with 2-fold Revenue Jump in Q1
A Blog by Biocon 